Technical Data Sheet

InVivoSIM bispecific anti-human CD3 x Claudin 18.2 (Gresonitamab Biosimilar)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number: **Lot Specific***
Volume: **Lot Specific***
Concentration: **Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein: **Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**SIMB0104**
Clone:	**Gresonitamab**
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Reported Applications:	*in vivo* functional assays *in vitro* functional assays ELISA
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤0.5EU/mg (≤0.0005EU/µg) Determined by LAL assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 µm filtration
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein A
RRID:	
Molecular Weight:	150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This Gresonitamab biosimilar antibody uses the same variable regions as the therapeutic antibody Gresonitamab, making it ideal for research use. Gresonitamab is a bispecific antibody in a scFv–scFv format that simultaneously targets human CD3 on T cells and Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed on gastric and other gastrointestinal tumor cells. By binding CD3 and Claudin 18.2, Gresonitamab redirects T cells to Claudin 18.2–expressing tumor cells, promoting immune synapse formation, T-cell activation, cytokine release, and targeted cytotoxicity. This T-cell–engaging mechanism enables potent and selective killing of tumor cells independent of native antigen presentation. Claudin 18.2 is normally restricted to differentiated gastric mucosa but becomes exposed and overexpressed in malignant tissues, making it an attractive tumor-associated antigen. This Gresonitamab biosimilar is well suited for studying T-cell redirection, Claudin 18.2–targeted tumor killing, gastrointestinal tumor biology, and the mechanistic basis of CD3-engaging bispecific antibody therapeutics.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/simb0104?bxcs=9k1b3a#tab_references or scan the QR code below.

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com